Vera Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 89.06 million compared to USD 32.61 million a year ago. Basic loss per share from continuing operations was USD 3.35 compared to USD 2.43 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
34.16 USD | +1.29% | -3.59% | +123.54% |
06-12 | Vera Therapeutics, Inc. Appoints Christy Oliger to the Board | CI |
05-28 | Vera Therapeutics Gets FDA Breakthrough Therapy Designation for Immunoglobulin A Nephropathy Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+123.54% | 1.84B | |
+20.40% | 46.93B | |
+37.72% | 39.08B | |
-8.26% | 38.48B | |
+29.58% | 31.01B | |
-12.26% | 26.14B | |
+11.07% | 25.88B | |
+35.33% | 12.53B | |
-6.62% | 11.36B | |
-12.37% | 10.65B |
- Stock Market
- Equities
- VERA Stock
- News Vera Therapeutics, Inc.
- Vera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022